CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Fermer

Original bioorganometallic complexes with high antiproliferative properties

Référence

01749-01

Statut des brevets

French patent application FR0854533 filed on July 03, 2008 and entitled “Complexes bioorganométalliques originaux à fort pouvoir antiprolifératif”

Inventeurs

Gérard JAOUEN
Anne VESSIERES-JAOUEN
Damian PLAZUK

Statut commercial

Exclusive or non-exclusive licenses

Laboratoire

Laboratoire de Chimie et Biochimie des Complexes Moléculaires (LCBCM, UMR7576), Paris, France

Description

CONTEXT

At present, four complexes based on cis-platin are used for their alkylating properties as anti-cancer drugs (Oxaliplatin, Nedaplatin, Cisplatin and Carboplatin). However, those molecules present high toxicity limiting their use in cancer therapy.

TECHNICAL DESCRIPTION

The invention describes new series of bioorganometallic cyclic complexes which are endowed with high and original antiproliferative properties. These molecules induce a selective apoptosis of cancerous cells and offer therefore an important therapeutic advance in the treatment of cancers.

DEVELOPMENT STAGE

The inventors have conducted in vitro essays. They are preparing to lauch in vivo essays.

BENEFITS

The advantage of this technology is that these bioorganometallic molecules induce apoptosis of cancerous cells at a very low IC50 (10 nanoMol) without affecting healthy cells. This selectivity associated to the absence of toxicity present a very promising profile for the development of efficient anticancer drugs.

INDUSTRIAL APPLICATIONS

The application of this invention concerns development of new anti-tumor compounds presenting a high therapeutic index.

 


Besoin de plus d'informations ?

Nous contacter
Fermer

Contactez-nous

  • This field is for validation purposes and should be left unchanged.
Fermer

Les brevets les plus récents